within Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX10_Laquinimod;

model Laquinimod
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 8.333333333333333e-07,
    adminDuration = 600,
    adminMass = 0.6 / 1000000,
    adminCount = 1,
    Vd = 0.15,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0009166666666666666,
    Tlag = 2700,
    Vdp = 0.095,
    k12 = 1.6666666666666667e-06,
    k21 = 1.6666666666666667e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Laquinimod</td></tr><tr><td>ATC code:</td><td>N07XX10</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.6</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>150</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Laquinimod is an oral immunomodulatory drug that was under investigation for the treatment of multiple sclerosis (MS) and Huntington's disease. It modulates immune responses and neurodegeneration, but development for MS was discontinued after phase III trials due to safety concerns and modest efficacy. It is not approved for clinical use as of 2024.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in healthy adult volunteers after single and multiple oral dosing.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N07XX10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Laquinimod;
